Tci Wealth Advisors, Inc. Regenxbio Inc. Transaction History

Tci Wealth Advisors, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 06, 2023	BUY	$20.4 - $24.73 $2,876 - $3,486	141 New	141 $3,000
Q2 2022 Jul 19, 2022	SELL	$19.35 - $35.04 $2,902 - $5,256	-150 Closed	0 $0
Q1 2022 Apr 29, 2022	BUY	$24.62 - $34.31 $3,693 - $5,146	150 New	150 $5,000
Q4 2021 Jan 24, 2022	SELL	$30.19 - $40.28 $3,260 - $4,350	-108 Closed	0 $0
Q3 2021 Oct 29, 2021	SELL	$29.09 - $45.68 $610 - $959	-21 Reduced 16.28%	108 $5,000
Q2 2021 Aug 02, 2021	BUY	$32.46 - $40.48 $2,661 - $3,319	82 Added 174.47%	129 $5,000
Q1 2021 Apr 29, 2021	BUY	$33.61 - $49.95 $1,579 - $2,347	47 New	47 $2,000
Q1 2020 Apr 14, 2020	SELL	$21.5 - $54.2 $838 - $2,113	-39 Closed	0 $0
Q4 2019 Jan 27, 2020	BUY	$34.54 - $44.87 $1,347 - $1,749	39 New	39 $2,000
Q3 2019 Oct 17, 2019	SELL	$31.84 - $50.88 $764 - $1,221	-24 Closed	0 $0
Q1 2019 Apr 11, 2019	BUY	$40.82 - $62.45 $979 - $1,498	24 New	24 $1,000
Q4 2018 Jan 17, 2019	SELL	$39.11 - $75.15 $430 - $826	-11 Closed	0 $0
Q3 2018 Nov 02, 2018	BUY	$65.0 - $82.15 $715 - $903	11 New	11 $1,000

193

43.5M

58.9K

58.4K

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $420M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

Get notified when there are updates to the investment portfolio of Tci Wealth Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on Tci Wealth Advisors, Inc. with notifications on news.